Mirum Pharmaceuticals (MIRM) Competitors $44.73 +1.25 (+2.87%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MIRM vs. ICPT, CDMO, UROV, CBAY, NGM, ASND, LEGN, ELAN, BPMC, and LNTHShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Avid Bioservices (CDMO), Urovant Sciences (UROV), CymaBay Therapeutics (CBAY), NGM Biopharmaceuticals (NGM), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Lantheus (LNTH). These companies are all part of the "medical" sector. Mirum Pharmaceuticals vs. Intercept Pharmaceuticals Avid Bioservices Urovant Sciences CymaBay Therapeutics NGM Biopharmaceuticals Ascendis Pharma A/S Legend Biotech Elanco Animal Health Blueprint Medicines Lantheus Intercept Pharmaceuticals (NASDAQ:ICPT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has better earnings and valuation, ICPT or MIRM? Intercept Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntercept Pharmaceuticals$285.71M2.78$221.82M-$1.48-12.84Mirum Pharmaceuticals$186.37M11.52-$163.41M-$2.02-22.14 Does the media favor ICPT or MIRM? In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 0 mentions for Intercept Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.69 beat Intercept Pharmaceuticals' score of 0.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Intercept Pharmaceuticals Neutral Mirum Pharmaceuticals Positive Is ICPT or MIRM more profitable? Intercept Pharmaceuticals has a net margin of -19.39% compared to Mirum Pharmaceuticals' net margin of -31.69%. Mirum Pharmaceuticals' return on equity of -41.22% beat Intercept Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Intercept Pharmaceuticals-19.39% -77.48% -11.99% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Does the MarketBeat Community favor ICPT or MIRM? Intercept Pharmaceuticals received 936 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 75.58% of users gave Mirum Pharmaceuticals an outperform vote while only 71.26% of users gave Intercept Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIntercept PharmaceuticalsOutperform Votes106671.26% Underperform Votes43028.74% Mirum PharmaceuticalsOutperform Votes13075.58% Underperform Votes4224.42% Which has more risk & volatility, ICPT or MIRM? Intercept Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Do analysts prefer ICPT or MIRM? Mirum Pharmaceuticals has a consensus target price of $57.73, suggesting a potential upside of 29.06%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Intercept Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intercept Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17 Do insiders & institutionals believe in ICPT or MIRM? 83.8% of Intercept Pharmaceuticals shares are held by institutional investors. 6.2% of Intercept Pharmaceuticals shares are held by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryMirum Pharmaceuticals beats Intercept Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Genesis Gold GroupTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15B$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-22.1410.35102.4617.58Price / Sales11.52362.011,234.85158.43Price / CashN/A52.6040.4736.33Price / Book9.2610.377.096.50Net Income-$163.41M$153.60M$119.65M$226.22M7 Day Performance0.52%3.92%2.06%3.76%1 Month Performance16.42%-6.78%-2.46%4.63%1 Year Performance39.78%33.23%33.95%29.20% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals4.3331 of 5 stars$44.73+2.9%$57.73+29.1%+39.8%$2.15B$186.37M-22.14140ICPTIntercept PharmaceuticalsN/A$19.00flatN/AN/A$794.77M$285.71M-12.84341CDMOAvid Bioservices3.5216 of 5 stars$12.25+0.2%$13.63+11.2%+126.1%$779.58M$142.36M-5.40371Positive NewsUROVUrovant SciencesN/A$16.24flatN/AN/A$531.75MN/A-3.4570CBAYCymaBay Therapeutics0.8744 of 5 stars$32.48flat$32.50+0.1%+81.5%$3.73B$31.07M-33.48101Analyst ForecastNGMNGM Biopharmaceuticals1.5887 of 5 stars$1.54-1.3%$1.55+0.6%+118.4%$128.53M$4.42M-0.90138ASNDAscendis Pharma A/S2.9978 of 5 stars$123.02-1.1%$191.77+55.9%+39.6%$7.54B$327.43M-15.22640Analyst UpgradeLEGNLegend Biotech1.4505 of 5 stars$39.75-1.0%$81.46+104.9%-31.9%$7.25B$285.14M-41.841,800ELANElanco Animal Health3.8657 of 5 stars$13.41-0.2%$17.14+27.9%+11.9%$6.63B$4.42B33.519,300BPMCBlueprint Medicines2.7235 of 5 stars$96.66+2.0%$122.11+26.3%+40.5%$6.02B$434.42M-45.81640Analyst RevisionLNTHLantheus4.6275 of 5 stars$87.32+1.0%$122.50+40.3%+32.5%$6.01B$1.50B14.53834Analyst DowngradePositive News Related Companies and Tools Related Companies Intercept Pharmaceuticals Competitors Avid Bioservices Competitors Urovant Sciences Competitors CymaBay Therapeutics Competitors NGM Biopharmaceuticals Competitors Ascendis Pharma A/S Competitors Legend Biotech Competitors Elanco Animal Health Competitors Blueprint Medicines Competitors Lantheus Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MIRM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRM Stock Alerts